Abbreviations used : bcl-2, B cell lymphoma protein-2 ; BD, bipolar affective disorder ; DD, differential display ; FCx, frontal cortex ; Li, lithium ; PEBP, polyomavirus enhancer-binding protein ; VPA, valproate.
The Mood-Stabilizing Agents Lithium and Valproate RobustlIncrease the Levels of the Neuroprotective Protein bcl-2 in the CNS
Article first published online: 13 JUN 2002
Journal of Neurochemistry
Volume 72, Issue 2, pages 879–882, February 1999
How to Cite
Chen, G., Zeng, W.-Z., Yuan, P.-X., Huang, L.-D., Jiang, Y.-M., Zhao, Z.-H. and Manji, H. K. (1999), The Mood-Stabilizing Agents Lithium and Valproate RobustlIncrease the Levels of the Neuroprotective Protein bcl-2 in the CNS. Journal of Neurochemistry, 72: 879–882. doi: 10.1046/j.1471-4159.1999.720879.x
- Issue published online: 13 JUN 2002
- Article first published online: 13 JUN 2002
- Manic-depressive illness;
- Transcription factors;
- Polyomavirus enhancer;
- binding protein 2;
- Differential display
Abstract : Differential display of mRNA was used to identify concordant changes in gene expression induced by two mood-stabilizing agents, lithium and valproate (VPA). Both treatments, on chronic administration, increased mRNA levels of the transcription factor polyomavirus enhancer-binding protein (PEBP) 2β in frontal cortex (FCx). Both treatments also increased the DNA binding activity of PEBP2αβ and robustly increased the levels of bcl-2 (known to be transcriptionally regulated by PEBP2) in FCx. Immunohistochemical studies revealed a marked increase in the number of bcl-2-immunoreactive cells in layers 2 and 3 of FCx. These novel findings represent the first report of medication-induced increases in CNS bcl-2 levels and may have implications not only for mood disorders, but also for long-term treatment of various neurodegenerative disorders.